Literature DB >> 16384851

Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease.

M J Simmonds1, J M Heward, J Carr-Smith, H Foxall, J A Franklyn, S C L Gough.   

Abstract

CONTEXT: Recently six DNA variants, two of which (M55V and 001Msp) are present in nuclear factor-kappaB inhibitors SUMO-4 and MAP3K7IP2 and four of which (fcrl3_3, fcrl3_4, fcrl3_5, and fcrl3_6) modulate nuclear factor-kappaB binding and production of the B cell surface molecule FCRL3, have been reported to be associated with a number of autoimmune diseases.
OBJECTIVE: The aim of this study was to investigate the association of these polymorphisms with disease in a large UK Caucasian Graves' disease (GD) data set.
DESIGN: The study was a case-control association study of six polymorphisms.
SETTING: The study was conducted at a UK academic department of medicine. PATIENTS OR PARTICIPANTS: Study population included 1056 GD patients and 864 controls.
INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Tests for association with disease were measured.
RESULTS: No association with disease was found for the M55V single-nucleotide polymorphism (SNP). Association was, however, found between GD and the 001Msp SNP [odds ratio (OR) 1.19 (95% confidence interval [CI]) 1.03-1.37], fcrl3_3 SNP [OR 1.17 (95% CI 1.02-1.34)], fcrl3_5 SNP [OR 1.18 (95% CI 1.04-1.35)], and fcrl3_6 SNP [OR 1.20 (95% CI 1.05-1.36)]. The 001Msp SNP was found to be associated with the presence of TSH receptor autoantibodies [OR 1.75 (95% CI 1.09-2.79)].
CONCLUSION: Functional evidence suggests that the 001Msp, fcrl3_3, fcrl3_5, and fcrl3_6 SNPs could cause changes in B cell signaling and activation pathways that could account for their association with GD. Further replication in independent data sets and fine mapping of the surrounding gene regions are needed to confirm the magnitude of the effect and location of the etiological variant(s) present within these gene regions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384851     DOI: 10.1210/jc.2005-1634

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

Review 1.  Role of genetic and non-genetic factors in the etiology of Graves' disease.

Authors:  M Marinò; F Latrofa; F Menconi; L Chiovato; P Vitti
Journal:  J Endocrinol Invest       Date:  2014-11-25       Impact factor: 4.256

2.  Association of Fc receptor-like 5 (FCRL5) with Graves' disease is secondary to the effect of FCRL3.

Authors:  Matthew J Simmonds; Oliver J Brand; Jeffrey C Barrett; Paul R Newby; Jayne A Franklyn; Stephen C L Gough
Journal:  Clin Endocrinol (Oxf)       Date:  2010-11       Impact factor: 3.478

Review 3.  GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis.

Authors:  Matthew J Simmonds
Journal:  Nat Rev Endocrinol       Date:  2013-03-26       Impact factor: 43.330

Review 4.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 5.  Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis.

Authors:  Yuta Kochi; Akari Suzuki; Ryo Yamada; Kazuhiko Yamamoto
Journal:  Nat Rev Rheumatol       Date:  2010-03-16       Impact factor: 20.543

6.  Four FCRL3 Gene Polymorphisms (FCRL3_3, _5, _6, _8) Confer Susceptibility to Multiple Sclerosis: Results from a Case-Control Study.

Authors:  Menghui Yuan; Longxiao Wei; Runsuo Zhou; Qianrong Bai; Yixin Wei; Wei Zhang; Yong Huang
Journal:  Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.590

7.  Pituitary tumor transforming gene binding factor: a new gene in breast cancer.

Authors:  Rachel J Watkins; Martin L Read; Vicki E Smith; Neil Sharma; Gary M Reynolds; Laura Buckley; Craig Doig; Moray J Campbell; Greg Lewy; Margaret C Eggo; Laurence S Loubiere; Jayne A Franklyn; Kristien Boelaert; Christopher J McCabe
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

8.  Investigation of the human FCRL1, 2, and 4 gene expressions in patients with rheumatoid arthritis.

Authors:  Ali Khanzadeh; Zahra Habibagahi; Ahmad Hosseini; Zahra Amirghofran
Journal:  Rheumatol Int       Date:  2016-05-18       Impact factor: 2.631

9.  Shared and unique susceptibility genes in a mouse model of Graves' disease determined in BXH and CXB recombinant inbred mice.

Authors:  Sandra M McLachlan; Holly A Aliesky; Pavel N Pichurin; Chun-Rong Chen; Robert W Williams; Basil Rapoport
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

10.  P-glycoprotein polymorphism in hypo- and hyper-thyroidism patients.

Authors:  Günfer Turgut; Mehmet Baştemir; Sebahat Turgut; Fulya Akin; Raziye Kursunluoglu; Bünyamin Kaptanoğlu
Journal:  Mol Biol Rep       Date:  2007-09-21       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.